As shown on the right, TES release the interleukin IL-2, which stimulates CAR-T cells to multiply, and anti-CD3 and anti-CD28, two antibodies that, similar to tumor antigens presented by an ...

Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.

Coya sees IL-2 as a molecule that can boost the number and power of regulatory T cells (Tregs), leading it to study it as a single agent, COYA 301, and pair the cytokine with the recombinant ...

These drugs are designed to deliver a double whammy to tumours, stimulating a local immune response with IL-2 via natural killer cells and cytotoxic T cells, and removing a brake on the immune ...